Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships

Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.

business partnership
Junshi/Coherus’s anti-PD-1 Loqtorzi gets into swing of partnering for combination therapies • Source: Shutterstock

Having successfully landed their anti-PD-1 Loqtorzi (toripalimab) in the US, Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. are set to jump-start a partnership bonanza for potential combination therapies using the immuno-oncology drug as the backbone.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By 

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By 

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By 

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

More from Therapy Areas

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By 

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.